Drug safety withdrawals: Who is responsible for notifying patients?

Pharmacoepidemiology and Drug Safety

Volumn 11, Issue 8, 2002, Pages 641-642

  Wolfe, Sidney M ^a  

^a Public Citizen Health Research Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERIVASTATIN; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

CLINICAL TRIAL; DRUG INDUSTRY; DRUG SAFETY; DRUG WITHDRAWAL; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HUMAN; LAW; PATIENT MONITORING; PHARMACIST; PHARMACY; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; RESPONSIBILITY; RHABDOMYOLYSIS; DRUG INFORMATION; ORGANIZATION AND MANAGEMENT; PATIENT EDUCATION;

DRUG INFORMATION SERVICES; HUMANS; PATIENT EDUCATION;

EID: 0036904515     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.776     Document Type: Editorial

References (6)

1. Schiff GD, Keehr LM, Sai TT, Bult J. High rates of patient unawareness of withdrawn lipid lowering drug combination in a public hospital clinic. Pharmacoepidemiol drug safe 2002; 11: 643-646.
2. NABP Model State Pharmacy Act and Model Rules - Fall 2001. Sections Addressing Recalls.
3. Personal communication, Carmen Catizone, Executive Director, NABP, 31 July 2002.
4. Personal communication, Gordon Schiff, MD, 26 July 2002.
5. Public Citizen Health Research Group petition to the FDA for box warning concerning rhabdomyolysis on all statin drugs, http://www.citizen.org/publications/release.cfm?ID = 7051[20 August 2001].
6. Furberg CD, Pitt B. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med 2001; 2: 205-207.